YAP1 and ovarian carcinoma: More specifically, it has been revealed that miR-141, derived from ovarian cancer, has preference to target YAP1 that is the critical mediator of the Hippo signaling pathway can abate the nuclear YAP1/TAZ ratio, as well as boost the reprograming of CAFs to fibroblasts with a pro-inflammatory phenotype and propel the formation of PMN67.